Loading, Please Wait...
SAN FRANCISCO and HOUSTON, April 22, 2019 (GLOBE NEWSWIRE) -- Vineti Inc., the leading software platform of record for personalized therapeutics, today announced a new partnership to advance and scale Marker Therapeutics’ T cell therapy pipeline. Marker Therapeutics is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications.
The goal of the partnership is to optimize logistics relating to Marker Therapeutics clinical stage pipeline of therapies in a safe and efficient manner. Personalized therapies require a software system to manage the complex supply chain associated with cell therapies. Vineti’s software platform will help Marker advance its clinical trials, support treatment locations and manufacturing sites, and support scheduling, logistics orchestration, manufacturing traceability, and overall visibility to each patient’s individual drug product status.
“With promising early clinical results in multiple cancer indications, we believe our therapies may represent the next major leap forward in cell therapy for cancer,” said Peter L. Hoang, President and CEO of Marker Therapeutics. “We look forward to initiating our Company-sponsored Phase 2 clinical trial in post-transplant acute myeloid leukemia later this year and believe we can benefit from the support of this personalized therapeutic enabling technology.”
Vineti’s platform will support Marker’s pipeline of autologous and allogeneic clinical-phase therapies with a digital orchestration platform to track, trace, align, and simplify the complex journey that underlies each patient’s personalized operations and logistics chain. Vineti is now supporting patients and clinicians in hundreds of medical centers worldwide and is rapidly expanding from the United States to Asia-Pacific and Europe.
“Vineti is honored to support Marker Therapeutics in its work to develop a new generation of T cell therapies,” said Vineti CEO Amy DuRoss. “The science behind T cell therapies is evolving exponentially, and Marker is at the forefront of developing these remarkable new options for patients in need.”
Vineti is the first cloud-based software platform to help safely and efficiently move patient-based personalized therapies through clinical development and into mainstream medicine at scale. The Vineti platform – configurable, cloud-based, secure and scalable – brings the best of enterprise software to advanced therapies. The Vineti solution automates traceability for personalized therapies, enables sophisticated, efficient treatment scheduling and manufacturing, and helps ensure conformation with regulations and standards. The platform supports the full continuum of personalized therapies and enabling workflows.
About Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker’s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize multiple tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. Once infused into patients, this population of T cells attacks multiple tumor targets and acts to activate the patient’s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling therapeutic product profile, as compared to current gene-modified CAR-T and TCR-based therapies. Marker is also advancing a number of innovative peptide- and gene-based immuno-therapeutics for the treatment of metastatic solid tumors, including the Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and the HER2/neu program (TPIV100/110) for breast cancer, currently in Phase II clinical trials. In parallel, Marker is developing a proprietary DNA expression technology named PolyStart™ that can enhance the ability of the immune system to recognize and destroy diseased cells.
About Vineti, Inc.
Vineti is the first commercial, configurable cloud-based platform to expand patient access to life-saving cell and gene therapies. Vineti was co-founded by GE and the Mayo Clinic to solve the key challenges patients, medical providers, biopharmaceutical companies and regulators face in the delivery and commercialization of individualized therapies. Now a fully independent company, Vineti offers a digital platform of record to integrate logistics, manufacturing and clinical data for personalized therapies. The Vineti software solution aligns and orchestrates the cell and gene therapy process and improve product performance overall. The Vineti platform supports the full continuum of patient-specific therapies, including cancer vaccines and autologous and allogeneic therapies. The platform can also be harnessed for drug products requiring companion diagnostics or REMS programs. The company is expanding rapidly, and the Vineti platform will be in use in hundreds of leading medical centers world-wide in 2019, on behalf of multiple biopharmaceutical partners. For more information, please visit www.vineti.com. Sign up to follow @vinetiworks on https://twitter.com/vinetiworks.
Forward-Looking Statement Disclaimer
This release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning Marker Therapeutics Inc.’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements”. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research and development activities relating to our non-engineered multi-tumor associated antigen specific T cell therapies; our TPIV200 and TPIV100/110 programs and our PolyStart™ program; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; and, the timing and success of our clinical trials, as well as multi-tumor antigen specific T cell clinical trials conducted by our collaborators. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company’s most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Director, PR and Scientific Communications